Alloy Therapeutics Acquires Spannerwerks to Expand Drug Development Capabilities
Alloy Therapeutics has acquired Seattle-based Spannerwerks, a leading drug development consulting firm, to strengthen its capabilities beyond discovery and into preclinical and clinical development. Spannerwerks will operate as a wholly owned subsidiary, with CEO Dara Lockert joining Alloy’s leadership team. The acquisition aims to accelerate partner programs, streamline drug development, and extend Alloy’s reach into the Pacific Northwest, combining discovery and development expertise to help biopharmaceutical innovators bring new therapies to patients faster. 
Alloy Therapeutics Acquires Spannerwerks to Expand Drug Development Capabilities